RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies
Open Access
- 1 January 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 11 (6), R187
- https://doi.org/10.1186/ar2879
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Immune regulation of bone loss by Th17 cellsArthritis Research & Therapy, 2008
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritisAnnals Of The Rheumatic Diseases, 2006
- Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibodyBiochemical and Biophysical Research Communications, 2006
- RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritisRheumatology, 2006
- Targeted therapy in rheumatoid arthritisWiener Medizinische Wochenschrift, 2006
- High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatmentArthritis & Rheumatism, 2002
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995
- The effect of an interleukin‐1 receptor antagonist protein on type ii collagen–induced arthritis and antigen‐induced arthritis in miceArthritis & Rheumatism, 1993
- Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritisArthritis & Rheumatism, 1990